Department of Pathology and Cell Biology, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, NY, USA.
Cancer Med. 2021 Apr;10(8):2680-2689. doi: 10.1002/cam4.3853. Epub 2021 Mar 15.
The detection of low-level persistent or relapsed B-cell neoplasms, particularly post-therapy, can be challenging, often requiring multiple testing modalities.
Here we investigate the utility of CD19-based selection of neoplastic B-cells (CD19S) as an enrichment strategy to improve the detection rate of cytogenetic abnormalities in post-therapy samples of B-cell neoplasms, especially those with low-level disease.
In a cohort largely comprised of post-therapy B-ALL and CLL samples, we performed fluorescence in situ hybridization (FISH) analysis on CD19-selected cells (CD19S FISH) in 128 specimens from 88 patients, and on non-selected cells (NS FISH) in a subset of cases. The FISH findings were compared with the concurrent flow cytometry (FC) results in all samples and molecular analysis in a subset.
CD19S FISH was able to detect cytogenetic aberrations in 86.0% of post-therapy samples with evidence of disease as determined by routine or MRD FC, compared to 59.1% of samples by NS FISH. CD19S FISH detected significantly higher percentages of positive cells compared to NS FISH (p < 0.001). Importantly, CD19S FISH enabled the detection of emergent subclones (clonal evolution) associated with poor prognosis.
CD19S FISH can be useful in daily diagnostic practice. Compared to NS FISH, CD19S FISH is quantitatively and qualitatively superior for the detection of cytogenetic aberrations in B-cell neoplasms, which are important for risk stratification and optimal management of patients with B-cell neoplasms, especially in the relapsed setting. Although CD19S FISH has a diagnostic sensitivity inferior to that of MRD FC, the sensitivity of this modality is comparable to routine FC for the evaluation of low-level disease in the post-therapy setting. Moreover, CD19S samples are invaluable for additional molecular and genetic analyses.
低水平持续或复发的 B 细胞肿瘤的检测,尤其是在治疗后,可能具有挑战性,通常需要多种检测方式。
本研究旨在探讨基于 CD19 的肿瘤 B 细胞(CD19S)选择作为一种富集策略,以提高 B 细胞肿瘤治疗后样本中细胞遗传学异常的检出率,尤其是在疾病水平较低的情况下。
在一个主要由治疗后 B-ALL 和 CLL 样本组成的队列中,我们对 88 例患者的 128 例标本进行了 CD19 选择细胞(CD19S FISH)的荧光原位杂交(FISH)分析,并对部分病例进行了非选择细胞(NS FISH)的分析。将 FISH 结果与所有样本的同期流式细胞术(FC)结果以及部分样本的分子分析进行比较。
CD19S FISH 能够在通过常规或 MRD FC 确定有疾病证据的 86.0%的治疗后样本中检测到细胞遗传学异常,而 NS FISH 仅能在 59.1%的样本中检测到。与 NS FISH 相比,CD19S FISH 检测到的阳性细胞比例显著更高(p<0.001)。重要的是,CD19S FISH 能够检测到与预后不良相关的新兴亚克隆(克隆进化)。
CD19S FISH 在日常诊断实践中是有用的。与 NS FISH 相比,CD19S FISH 在检测 B 细胞肿瘤的细胞遗传学异常方面具有定量和定性优势,对于 B 细胞肿瘤的风险分层和患者的最佳管理至关重要,尤其是在复发时。尽管 CD19S FISH 的诊断灵敏度低于 MRD FC,但该方法在评估治疗后低水平疾病时的灵敏度与常规 FC 相当。此外,CD19S 样本对于额外的分子和遗传分析非常有价值。